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Introduction
The independent lineages of mature hematopoietic cells are ini-
tially generated from stem cells that are extrinsically and intrinsi-
cally regulated to traverse multiple, distinct developmental stages. 
A host of tissue- and stage-affiliated transcription factors and 
signaling pathways plays essential roles in achieving the final dif-
ferentiated state of each hematopoietic lineage. The appropriate 
contribution of different factors and signaling pathways to each 
lineage-specific transcriptional network ultimately determines the 
developmental fate and activity of each hematopoietic cell type.
Following the circulation of immature hematopoietic cells 
from the bone marrow to the thymus, early T lineage progenitors 
(ETPs) are generated and undergo development into double-neg-
ative cells (stages DN2 to DN4), in which neither the CD4 nor the 
CD8 coreceptor is expressed. β-Selection, one of several critical 
steps during T cell development, occurs at the DN3 stage, and only 
thymocytes that successfully rearrange the T cell receptor (TCR) β 
locus (and therefore express a functional pre-Tα/TCRβ complex) 
are licensed to differentiate further and transition to the DN4 and 
immature single-positive (SP; CD4–CD8+TCRblo) stages. As those 
immature SP cells become double positive (DP) for the CD4 and 
CD8 coreceptors, the TCRα locus rearranges. DP cells that express 
a functional TCRαβ receptor on their cell surface then undergo 
positive selection and move into the CD4+CD8lo intermediate 
stage. CD4+CD8lo cells are still uncommitted to a specific T cell 
cytotoxic or helper function, and thus CD4 versus CD8 lineage 
choice occurs at this stage. Persistent TCR signaling contributes to 
CD4 lineage fate, and cells differentiate into CD4 SP cells, while 
cessation of TCR signaling and initiation of IL-7 signaling con-
tribute to CD8 lineage fate. CD4 and CD8 cells then exit the thy-
mus and circulate to peripheral lymphoid organs where they can 
acquire effector functions as either helper T cells (CD4 lineage) or 
cytotoxic T cells (CD8 lineage) (reviewed in refs. 1, 2).
Following our original identification of transcription factor 
GATA3 in chicken, mouse, and human cells (3, 4), we and oth-
ers showed that it is expressed throughout T cell development, 
although its level varies significantly between stages, from abun-
dant expression in CD4 cells to quite low expression in CD8 cells 
(5–11). Numerous studies have demonstrated the crucial impor-
tance and essential contributions of GATA3 to different stages 
of T cell development, in ETP (12), DN1 (13), the DN3-to-DN4 
transition (14), CD4 cells (14, 15), and Th2 cells (16, 17). Although 
GATA3 is dispensable for the initial generation of CD8 cells, it 
is required for their final maturation, maintenance, and function 
(18, 19). In addition to the T cell lineage, GATA3 plays impor-
tant roles in the innate immune system (20–22) and in NK cell 
development (23, 24). In contrast, B lymphocyte development 
requires Gata3 repression (25).
Although its pervasive expression is essential throughout 
normal T cell development, forced expression or underexpres-
sion of GATA3 can trigger pathological consequences (26–30), 
for example, generating T cell lymphoma in transgenic (Tg) mice 
(27) or elevated susceptibility to allergic airway inflammation (31, 
32). Additionally, GATA3 is aberrantly expressed in Hodgkin’s 
lymphoma (33) and controls cytokine expression, which plays an 
important role in the pathogenesis of Hodgkin’s disease (34). Hap-
loinsufficient GATA3 mutation in humans leads to HDR syndrome 
(hypoparathyroidism, sensorineural deafness, and renal disease; 
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The results of analysis of these offspring indicated that 3 of the 
pups displayed evidence for incorporation of both loxP sites (either 
in cis or trans), while 3 of the animals had heterozygous deletions 
and 1 of the animals had homozygous deletions of the entire 7.1-
kbp sequence lying between the two gRNA sites (Supplemental 
Figure 2). Since the two gRNAs targeted for the 5′ and 3′ ends of 
Tce1 were injected at the same time, double-strand breaks prob-
ably occurred simultaneously at both ends and resulted in dele-
tion of Tce1 by nonhomologous end joining, as previously reported 
(44). Sequencing across the two sites in amplified genomic DNA 
under conditions that would not detect the germ line configura-
tion confirmed deletion of Tce1 from at least one allele (Supple-
mental Figure 2). In this study, we focused on the deleted alleles 
and did not further analyze the potential floxed alleles.
Next, we examined thymocytes, peripheral blood, and spleens 
for possible alterations in hematopoietic and T cell development 
and/or Gata3 mRNA expression that could be detected as a conse-
quence of Tce1 loss in both homozygous and heterozygous F3 and 
subsequent generation mice (Figure 1, B–D, and Supplemental 
Figure 3), as previously shown (12). As anticipated, homozygous 
loss of Tce1 (Tce1–/–) led to a reduction in the number of ETPs (62% 
of that of heterozygous controls), and Gata3 mRNA in the remain-
ing ETPs was only 52% of that of controls (Figure 1B). In contrast, 
the number of Tce1–/– DN2 and DN3 stage cells was unaltered com-
pared with that of controls, although Gata3 mRNA levels in DN2 
thymocytes were reduced (83% of that of heterozygous controls; 
Figure 1B). This modest reduction in the number of early stage T 
cells in Tce1–/– mice is similar to the phenotype observed in Gata3 
hypomorphic mutants, which express low levels (10%–20% of that 
of wild-type animals) of a GATA3-EGFP fusion protein in thymo-
cytes of adoptively reconstituted animals (12). In Tce1–/– DN4 and 
DP stages, Gata3 mRNA was reduced to 55% and 45% of that of 
controls, respectively, while the total number of cells was normal.
The data shown here demonstrate that T cell development is 
severely affected in Tce1–/– mice. The number of CD4 SP thymo-
cytes was reduced to 30% of that of controls, and Gata3 mRNA 
abundance in the surviving CD4 thymocytes was reduced to 42% 
of that of control values (Figure 1B), while, in contrast, the num-
bers of CD4 SP thymocytes and mRNA levels of Gata3 in CD8 
T cells were comparable in Tce1–/– and heterozygous control mice 
(Figure 1B). Similarly, the number of CD4 T cells in Tce1–/– mice 
was reduced in the peripheral blood (30% of that of controls, Fig-
ure 1C) and spleens (39% of that of controls, Figure 1D) in com-
parison to those in controls, while the number of peripheral CD8 
T cells was unaffected. The CD4 T cell–specific defect observed 
in Tce1–/– mutant mice is consistent with previous studies in which 
the Gata3 gene was conditionally ablated by a Cd4-Cre Tg (14, 15). 
The normal level of Gata3 mRNA found in surviving peripheral 
CD4 T cells suggests that cells retaining less abundant GATA3 
expression cannot survive or that their proliferation is retarded 
at this stage. To further characterize the peripheral CD4 T cells 
generated in the absence of Tce1, we analyzed expression of CD44 
and CD62L, which can distinguish naive T cells from memory T 
cells (45). While the CD44loCD62L+ naive T cell number was sig-
nificantly reduced in splenic CD4 T cells isolated from Tce1–/– mice 
when compared with that in heterozygous controls (Supplemental 
Figure 4), the CD44hiCD62L– memory T cell number was compa-
ref. 35). Collectively, these data highlight the conclusion that nor-
mal T cell development requires quantitatively and qualitatively 
stringent control over GATA3 expression.
We previously reported the identification of a T cell–specific 
Gata3 enhancer, which we originally named TCE-7.1 (referred 
to hereafter as Tce1) (36). Tce1 is a 7.1-kb segment of the locus 
located 280 kbp 3′ to the Gata3 structural gene. We showed that 
this enhancer induces T lymphocyte–specific transcription of 
reporter genes throughout T cell development and enhances NK 
cell expression (36). However, multiple additional mechanistic 
questions emerged from that study. For example, is Tce1 necessary 
for Gata3 regulation of T cell development in vivo or does it act 
in a redundant fashion with additional currently unidentified cis 
elements? What is the mechanism of action of Tce1 (that is, how 
does Tce1 differentially regulate the precise differential abun-
dance of GATA3 at multiple T cell developmental stages)? Finally, 
what transcription factors elicit appropriate Gata3 transcriptional 
responses in a stage-specific manner through this enhancer?
Here, we report that homozygous genetic loss of Tce1 in vivo 
using CRISPR/Cas9-mediated genome editing impairs at least two 
critical T cell stages: the initial generation of ETP and the devel-
opment of CD4 lymphocytes. We also show that Tce1 contains a 
critical enhancer sequence defined by a 1.2-kbp core fragment that 
regulates transcription in developmental stages from ETP through 
to naive T cells. Previous studies showed that Gata3 is regulated 
by transcription factors HEB (37, 38), T cell factor 1 (TCF-1) (39), 
and RBP-J/CSL (40), all of which bind to the promoter. We show 
that the binding of those factors to the Gata3 promoter alone is 
insufficient to confer T cell–specific activation to Gata3 but that 
the same factors also bind avidly within Tce1, providing a possible 
explanation for how Gata3 regulation mediated through Tce1 can 
be responsive to the Wnt (41) and Notch (40) signaling pathways.
Results
Tce1 is necessary for ETP and CD4 T cell development. One of the 
central questions that emerged from our previous study (36), 
which showed that Tce1 was sufficient for reporter gene T cell–
specific activation throughout T cell development, was whether 
Tce1 is also necessary for Gata3 activation in vivo. To address this 
question, we targeted the genomic locus using CRISPR/Cas9 
guide RNAs (gRNAs) (42) corresponding to sequences on either 
side of the 7.1 kbp that define the boundaries of Tce1 and, at the 
same time, introduced single-stranded oligonucleotides bear-
ing genomic homology that would additionally incorporate loxP 
sequences into the two targeted sites (Figure 1A and Supplemental 
Figure 1; supplemental material available online with this article; 
doi:10.1172/JCI83894DS1). gRNAs were selected after exami-
nation of the genome for similar sequences that had the fewest 
potentially related off-target homologies. In this manner, we antic-
ipated, after injection of the constructs into fertilized murine ova, 
the generation of germ line mutants in which Tce1 would be unal-
tered in function until conditional deletion of the enhancer after 
Cre recombinase excision. Both gRNA and CRISPR/Cas9 vectors 
were microinjected into 441 fertilized oocytes of F2 animals gen-
erated by crossing C57BL/6J males already bearing the Mx1-Cre 
Tg (43) with wild-type SJL females; 77 live pups were screened by 
PCR for mutations incorporated at the gRNA-targeted sequences.
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ETP and CD4 stages in the thymus as well as in CD4 T cells in 
the peripheral blood and spleen. Tce1 also contributes to Gata3 
expression in DN4 and DP stage cells, even though the number 
of those cells that accumulate is normal whether Tce1 is pres-
ent or absent. We concluded that Tce1 is a critical regulator of 
the Gata3 gene in a subset of thymocytes. Since the phenotypes 
rable in the two genotypes. The data suggest that compensatory 
expansion or accumulation of memory T cells in Tce1-deleted 
mutants must exist. The data clearly demonstrate that CD4 T cell 
development is severely compromised by deletion of Tce1 in mice.
Collectively, the data demonstrate that Tce1 is necessary 
for Gata3 gene expression and therefore T cell development in 
Figure 1. In vivo genome deletion of Tce1. (A) Two CRISPR/Cas9 plasmids expressing gRNAs that correspond to sequences surrounding the 7.1 kbp that 
define the boundaries of Tce1 were coinjected into mouse fertilized oocytes. Tce1-deleted mutant allele founder (F0) mice were intercrossed to obtain 
homozygous deletion mutant mice. (B) Thymocytes, (C) peripheral blood cells, and (D) splenocytes isolated from F2 animals at 5 to 6 weeks of age bearing 
homozygous (white circle) or heterozygous (black circle) deletions of Tce1 were analyzed for cell surface expression of T cell stage–specific markers. The 
absolute numbers of Lin–cKithiCD25– (ETP), Lin–cKithiCD25+ (DN2), Lin–cKitlo/–CD25+ (DN3), Lin–cKitlo/–CD25– (DN4), CD4+CD8+ (DP), CD4+CD8–CD3+TCRβ+ 
(CD4 SP), and CD4–CD8+CD3+TCRβ+ (CD8 SP) thymocytes are shown at the top. Each stage of T cells was isolated by flow cytometry and analyzed for the 
expression of Gata3 mRNA, as normalized to Hprt by qRT-PCR. Each circle represents an individual mouse, and black bars represent the average for each 
genotype. Data are representative of the summary of 2 independent experiments. *P < 0.05 by Student’s t test.
Downloaded from http://www.jci.org on April 21, 2016.   http://dx.doi.org/10.1172/JCI83894
The Journal of Clinical Investigation R e s e a R c h  a R t i c l e
8 6 8 jci.org   Volume 126   Number 3   March 2016
was not possible. Each of the EGFP reporter plas-
mids was injected into fertilized ova to generate 
founder (F0) Tg mice (referred to as Tg2.9 and 
Tg4.2 mice, respectively), since we had previously 
demonstrated that T cell cis element(s) could 
be rapidly and efficiently identified by founder 
analysis (36). One important fact to keep in mind 
for this analysis is that the Tce1-driven EGFP 
reporter transgenic mouse line (TgTce1) is a stable, 
established Tg line, while Tg2.9 mice and all other 
Tg mice examined in this study are founders. 
Therefore, it is extremely difficult to quantita-
tively compare data among different founder animals or between 
founders and lines.
When we analyzed reporter gene expression in T cells from 
peripheral blood, we found that EGFP was expressed in CD4 T 
cells in the majority of Tg2.9 mice but not in Tg4.2 mice (Table 1 and 
Supplemental Figure 5A). Furthermore, and as is also true for TgTce1 
mice, EGFP expression was observed in Tg2.9 animals at multiple 
stages, including ETP and CD4 T cells (Figure 3 and Table 2). 
In addition to αβTCR+ T cells, γδTCR+ thymocytes expressed 
EGFP (Supplemental Figure 6 and Supplemental Table 1). In con-
trast, EGFP expression was never detected in thymocytes from 
Tg4.2 mice (Figure 3 and Table 2), and neither group of founders 
expressed EGFP in other hematopoietic lineages (Supplemental 
Table 2). These results show that the 2.9-kb fragment, but not the 
4.2-kb fragment, is sufficient to direct transcription of reporter 
genes throughout thymocyte development.
Since the 2.9-kb Tce1 fragment harbors two clusters of CNSs 
(Figure 2A), we wondered whether either could function as an 
independent T cell–specific enhancer and whether both are 
required for transcription in T cells. Therefore, we bisected the 
observed in Tce1–/– mutant mice are milder than those in mice 
in which the Gata3 gene itself is ablated and since diminished 
accumulation of GATA3 transcripts was detected in the affected 
stages of T cells, a redundant but currently unidentified second 
enhancer(s) appears to at least partially compensate for the loss 
of in Tce1 in vivo (see Discussion).
Dissection of the molecular architecture that confers Tce1 activity 
during thymocyte development. Given that homozygous deletion of 
Tce1 from the genome resulted in compromised T cell develop-
ment (Figure 1) and that Tce1 is capable of driving transcription 
of a reporter gene at all T cell developmental stages (36), one 
can imagine several possibilities for how Tce1 might function. For 
example, Tce1 might contain only a single cis element that is capa-
ble of regulating transcription at all T cell developmental stages 
in response to modulated signals received from signal-activated 
transcription factors, as they respond to intracellular or extracel-
lular differentiation signals. Alternatively, the 7.1-kbp Tce1 might 
harbor multiple cis elements, each of which additively or synergis-
tically contributes to distinct stages of T cell development.
In order to experimentally distinguish among these possibil-
ities, we prepared multiple fluorescent reporter constructs, each 
directed by the Gata3 1b promoter (46) and bearing various Tce1 
fragments (Figure 2B, shown in detail in Figure 3A, Figure 4A, Fig-
ure 5A, Figure 6A, and Figure 7A). Tg animals whose transcription 
was directed by an individual fragment of Tce1 (e.g., the 1.2-kb 
fragment shown in Figure 4A) are designated as such (e.g., Tg1.2), 
while deletion of each part of Tce1 from the whole is designated 
by a preceding Δ (e.g., TgΔ1.2, Figure 5A). The details for plasmid 
constructions are described in the Supplemental Methods.
We first bisected Tce1 into two 2.9-kb and 4.2-kb fragments, 
respectively (Figure 3A). Both fragments contained multiple con-
served noncoding sequences (CNSs; Figure 2A) as well as dozens 
of putative binding sites for T cell–affiliated transcription factors, 
so an a priori evaluation of their transcriptional potential in T cells 
Figure 2. Truncation and deletion mutants of Tce1. (A) 
Diagrams of the mouse Gata3 locus and Tce1. Sequence 
homology between mouse and human Tce1 sequences 
is depicted as a Manhattan diagram. Restriction 
enzyme recognition sites Sal I (S), BstII (B), XhoI (X), 
ApaLI (A), and KpnI (K) are shown. The genome position 
of Tce1 is mm9 chr2, position 9,515,156 to 9,522,270. (B) 
The structure of the EGFP reporter plasmid used in this 
study is depicted.
Table 1. EGFP expression in the peripheral blood of F0 Tg mice
Tg No. CD4+EGFP+ Tg mice/no. Tg mice (PCR+)
Tg2.9 9/14
Tg4.2 0/6
Tg1.2 4/7
Tg1.7 0/4
TgΔ1.2 0/7
TgΔ1.7 10/14
TgΔ1.5 20/24
TgΔ2.7 4/7
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that all of them expressed EGFP in peripheral CD4 T cells (Tables 
1 and 2). Therefore, the EGFP expression in those mice confirmed 
that these sequences were not required for Tce1 enhancer activity 
in peripheral CD4 T cells. These data show that the 1.2-kb T cell 
enhancer fragment within Tce1 is also necessary for reporter gene 
transcription in T cells and, taken together with the data shown in 
Figure 1, that this fragment functions as an enhancer core element 
in vivo for Gata3 T cell–specific transcription. The data also show 
that the extended Gata3 promoter, either alone or when combined 
with inactive fragments of Tce1, is not sufficient for T cell activation.
Transcription of Gata3 in Th2 cells requires cooperation of mul-
tiple elements within Tce1. GATA3 is necessary for the differentia-
tion and function of Th2 cells (5), and we have shown that Tce1 can 
2.9-kb fragment into 1.2-kb and 1.7-kb subclones that contained 
the individual CNSs (Figure 2A and Figure 4A), used these to gen-
erate new Tg founders (Tg1.2 and Tg1.7 mice), and analyzed periph-
eral blood from those F0 mice as before. We found that EGFP was 
expressed in the peripheral blood CD4 T cells in the majority of 
Tg1.2 mice, while EGFP expression was essentially absent in Tg1.7 
mice (Table 1 and Supplemental Figure 5B). Detailed analyses of 
their thymocytes revealed that Tg1.2 mice again exhibited EGFP 
expression at multiple stages of thymopoiesis (Figure 4, B and C; 
Table 2; Supplemental Figure 6B; and Supplemental Table 1), and, 
as before, EGFP expression was not observed in other kinds of 
hematopoietic cells (Supplemental Table 2). Taken together, the 
data show that a 1.2-kb fragment within Tce1 contains multistage 
T cell enhancer activity and that this fragment is suf-
ficient to drive the transcription of a reporter gene in 
all stages of thymocytes.
We next asked whether this 1.2-kb Gata3 Tce1 
fragment was also necessary for the transcription of 
a reporter gene in T cells. To answer this question, we 
prepared another EGFP reporter plasmid in which 
the 1.2-kb sequence was deleted from full-length 
Tce1 (Figure 5A) and generated additional F0 Tg mice 
(TgΔ1.2 mice). None of the F0 TgΔ1.2 mice expressed 
EGFP in peripheral CD4 T cells (Table 1 and Supple-
mental Figure 5C) or in thymocytes (Figure 5, B and 
C), except possibly at the DN4 stage (Table 2). We 
also analyzed TgΔ1.7, TgΔ1.5, and TgΔ2.7 mice and found 
Table 2. EGFP expression at each thymocyte developmental stage in F0 Tg mice
Tg No. EGFP+ cells by stage in Tg mice/no. Tg mice (PCR+)
ETP DN2 DN3 DN4 DP CD4 SP CD8 SP
Tg2.9 7/8A 6/8A 8/8A 8/8A 8/8A 8/8A 8/8A
Tg4.2 0/6 0/6 0/6 0/6 0/6 0/6 0/6
Tg1.2 4/7 2/7 3/7 4/7 4/7 4/7 4/7
Tg1.7 0/4 0/4 0/4 0/4 0/4 0/4 0/4
TgΔ1.2 0/7 0/7 0/7 3/7 0/7 0/7 0/7
AEight of nine Tg2.9 mice whose EGFP expression in peripheral T cells was positive were 
analyzed.
Figure 3. A 2.9-kb fragment of Tce1 drives thymocyte-specific transcription of reporter genes. (A) Illustration of truncated 2.9-kb and 4.2-kb Tce1 frag-
ments. Restriction enzyme recognition sites are shown. EGFP expression in (B) ETP and (C) CD4+CD8–TCRβ+ (CD4 SP) cells from Tg2.9, Tg4.2, TgTce1, and Tg1b.EGFP 
mice and in wild-type thymocytes. Note that Tg2.9 and Tg4.2 mice are F0 mice, while Tg
Tce1 and Tg1b.EGFP mice are from Tg lines established previously. Data are 
representative of 2 independent experiments; the gray shaded histogram represents  expression in Tg2.9, Tg4.2, or TgTce1, respectively; the solid line histogram 
represents expression in Tg1b.EGFP; and the dashed line histogram represents expression in wild-type mice.
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direct the transcription of a reporter gene in peripheral Th2 cells as 
well as in thymocytes, although significant induction of EGFP at 
the Th2 stage was not observed, as it is in endogenous GATA3 (36). 
This observation indicates that Tce1 activity alone cannot account 
for all GATA3 expression in Th2 cells and that at least one addi-
tional cis element may be required to achieve full GATA3 abun-
dance. In order to clarify the mechanism by which Tce1 contributes 
to GATA3 expression in Th2 cells, we analyzed EGFP expression 
of reporter Tg mice bearing Tce1 fragments and found that naive 
CD4 cells from both Tg2.9 and Tg1.2 mice expressed EGFP (Fig-
ure 6 and Table 3). We then stimulated naive CD4 T cells under 
Th2-polarizing conditions in vitro (see Methods) and, surprisingly, 
discovered that EGFP expression was eliminated in almost all of 
the Tg2.9 and Tg1.2 Th2 cells, comparable to reporter expression in 
Tg4.2 and Tg1.7 mice (Figure 6 and Table 3). These data show that 
neither of the initially bisected larger Tce1 fragments is sufficient 
for the transcription of the EGFP reporter gene in Th2-polarized 
cells, while Tce1 itself does confer such activity. We concluded that 
multiple individual cis elements, located within both the 2.9-kb 
and 4.2-kb fragments, must collaborate to activate Gata3 Th2 cell–
specific transcription.
Given that the 1.2-kb enhancer core fragment of Tce1 is nec-
essary for reporter transcription throughout thymocyte develop-
ment, we asked whether it is also necessary for Th2 transcription. 
We determined that neither naive CD4 T cells nor Th2-polarized 
cells that were developed from TgΔ1.2 mice exhibited EGFP fluo-
rescence (Figure 7B and Table 3). Thus, the 1.2-kb core enhancer 
region is necessary, but not sufficient, for reporter gene tran-
scription in Th2 cells.
In order to identify which elements within Tce1 are involved 
in the regulation of Th2 transcription, we generated Tg mice 
bearing internal deletions of Tce1 (Figure 7A) and analyzed their 
expression in naive CD4 T cells and in Th2 cells (Figure 7B). Since 
the data indicate that sequences within the 4.2-kb fragment are 
involved in Th2 transcription and this fragment contains several 
CNSs (Figure 2A), we examined reporter gene expression after 
individually deleting either the 2.7-kb (TgΔ2.7) or the 1.5-kb (TgΔ1.5) 
segments of Tce1. As shown in Figure 7B and Table 3, naive CD4 T 
cells from TgΔ2.7 and TgΔ1.5 mice both expressed EGFP. After those 
cells were stimulated to undergo Th2 differentiation, both geno-
types retained EGFP expression (Table 3). These results indicate 
that the 2.7-kb and 1.5-kb segments of Tce1 are both at least par-
tially redundant for Th2 stimulatory activity and that the 2.7-kb 
fragment may contribute more robustly than the 1.5-kb fragment 
to Th2 stimulatory activity in collaboration with the 1.2-kb Tce1 
enhancer core fragment.
We also asked whether the 1.7-kb fragment of Tce1 contrib-
utes to transcription in Th2 cells by generating additional deletion 
mutants (TgΔ1.7). Naive CD4 T cells from TgΔ1.7 mice expressed 
EGFP (Figure 7B and Table 3), as expected. Th2-polarized stim-
Figure 4. A 1.2-kb fragment of Tce1 drives thymocyte transcription of reporter genes. (A) Illustration of truncated 1.2-kb and 1.7-kb Tce1 fragments. 
Restriction enzyme recognition sites are shown. EGFP expression in (B) ETP and (C) CD4+CD8–TCRβ+ (CD4 SP) cells from Tg1.2, Tg1.7, TgTce1, Tg1b.EGFP, and wild-
type mice. Note that Tg1.2 and Tg1.7 mice represent expression in F0 Tg mice. Data are representative of 2 independent experiments. The gray shaded histo-
gram represents  expression of Tg1.2, Tg1.7, or TgTce1, respectively; the solid line histogram indicates the expression of Tg1b.EGFP; and the dashed line histogram 
represents EGFP expression in wild-type thymocytes.
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ulated T cells also expressed EGFP, although the number of mice 
that were EGFP+ at the Th2 stage was reduced (Table 3). These 
results suggest that the 1.7-kb region may also modestly contribute 
to Th2-specific transcription.
We concluded that both the 1.2-kb Tce1 enhancer core and 
either the 2.7-kb or the 1.5-kb fragments within the adjacent 4.2-
kb fragment are required for transcription of reporter genes in Th2 
stage cells. These results imply that the transcriptional mecha-
nisms mediated by Tce1 during T cell development are complex, 
and at least partially redundant through activities residing wholly 
within Tce1, and, therefore, that the amalgam of cis contributions 
to T cell enhancement of Gata3 transcription contained within 
Tce1 may more closely resemble a locus control region (47) or 
super-enhancer (48) (i.e., an extended genomic domain harboring 
clusters of constituent enhancers) rather than a classical mono-
tonic enhancer activity.
TCF-1, HEB, and RBP-J regulate Gata3 transcription by bind-
ing within Tce1. Several transcription factors have been proposed 
as direct or indirect upstream regulators of Gata3 in T cells. For 
example, TCF-1, a major regulator of T cell developmental activ-
ity, which is required for early stages of thymopoiesis (39), appears 
to not be required for DN2 to DN4, DP, and SP stages (49) but is 
reinduced for the acquisition of Th2 fate. E-box transcription fac-
tor HEB has similarly been implicated as a critical determinant of 
T cell developmental decisions (37, 38), and T cell development 
has been shown to critically require Notch pathway input at mul-
tiple stages (40, 50–52). Since Tce1 contains dozens of putative 
transcription factor–binding sites, including sites for all 3 of these 
proposed upstream regulators, we next examined which of these 
factors might regulate Gata3 through Tce1.
TCF-1 belongs to the TCF/LEF transcription factor family that 
binds to DNA through an HMG box and is strongly expressed in T 
cells (53). TCF-1 has been shown to be essential for multiple stages 
of T cell development and for Gata3 transcription (39, 49, 54–56). 
Enforced expression of TCF-1 induces Gata3 in Thy1+CD25+ T lin-
eage cells when developed in vitro (39). While researchers have 
reported that TCF-1 binds to the Gata3 promoter (39), it is unknown 
whether TCF-1 binds to Tce1 to regulate Gata3 expression in T cells. 
Tce1 contains multiple TCF/LEF-binding sites that are conserved 
between mice and humans (Figure 8A and Supplemental Figure 7), 
so we investigated TCF-1’s occupancy at those sites by ChIP assays. 
The binding of TCF-1 to Axin2, a known target gene of TCF-1 in 
T cells (39), was used as a positive control (Figure 8B).
We found that TCF-1 bound to site e (Figure 8A and Supple-
mental Table 3), located within the 1.2-kb enhancer core element, 
in total thymocytes (Figure 8B). Since more than 80% of thy-
mocytes are DP cells, we also examined whether TCF-1 binds to 
this enhancer at other T cell developmental stages. As shown in 
Figure 8B, TCF-1 bound to sequences within fragment e (Figure 
8A and Supplemental Table 3) in both DN and CD4 thymocytes. 
Although TCF-1 occupies the Gata3 promoter in DN stage cells 
(39), we previously demonstrated that a YAC, which includes 
both Gata3 promoters (1a and 1b) but not Tce1, is insufficient to 
drive Gata3 transcription in DN cells (36), an observation recon-
firmed here (e.g., Figure 3B shows the failure to express EGFP in 
transgenic mice bearing only the Gata3 1b promoter, Tg1b.EGFP). 
Therefore, TCF-1 appears to directly control Gata3 expression 
through the Tce1 enhancer.
During late T cell development, TCF-1 functions to promote 
specification to the CD4 lineage by regulating Th-POK in DP 
cells, while TCF-1 and Runx3 collectively repress Cd4 in cells that 
are committed to the CD8 lineage (49, 57). Because the absence 
of TCF-1 during DP through CD4+CD8lo intermediate cells does 
not affect the expression level of Gata3 (49), TCF-1 may not be 
Figure 5. The Tce1 1.2-kb fragment is neces-
sary for thymocyte reporter gene transcrip-
tion. (A) Illustration of the 1.2-kb deletion 
mutant Tce1 fragment. Restriction enzyme 
recognition sites are shown. EGFP expression 
in (B) ETP and (C) CD4+CD8–TCRβ+ (CD4 SP) 
cells from TgΔ1.2, TgTce1, Tg1b.EGFP, and wild-type 
mice. Note that TgΔ1.2 mice represent expres-
sion in F0 mice, while Tg
Tce1 and Tg1b.EGFP mice are 
from previously described Tg lines. Data are 
representative of 2 independent experiments. 
The gray shaded histogram represents  expres-
sion of TgΔ1.2 or TgTce1, respectively; the solid 
line histogram indicates expression of Tg1b.EGFP; 
and the dashed line histogram represents the 
expression in wild-type mice.
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regulatory role there (66), it seems possible that HEB-E2A as well 
as HEB-Id3 heterodimers could directly contribute to precision 
tuning of Gata3 expression through Tce1.
Notch is a transmembrane receptor, and Notch signaling is 
essential, not only for T cell development, but also for cell fate 
decisions and cellular proliferation in numerous other tissues (52, 
67, 68). After Notch ligand binds to Notch receptor, the cleaved 
receptor (the intracellular domain of Notch [ICN]) translocates to 
the nucleus to form a ternary complex with mastermind and tran-
scription factor RBP-J, converting it from a transcriptional repres-
sor to an activator (69, 70). During early T cell development and 
Th2 differentiation, Notch signaling induces Gata3 expression 
a principal component in the induction of Gata3 at those stages. 
Instead, TCF-1 may function through Tce1 to maintain the expres-
sion of Gata3 after the CD4/CD8 lineage determination decision, 
perhaps by differentially increased binding to sequences within 
fragment f (Figure 8A and Supplemental Table 3) to reinforce 
CD4 commitment (Figure 8B). The binding of TCF-1 to frag-
ments e and f (Figure 8A and Supplemental Table 3) is consistent 
with previously published ChIP-seq data from total thymocytes 
(GSE46662 and Supplemental Figure 7) (58).
Transcription factor HEB (59) is an E-box protein belonging 
to the bHLH family. HEB, like TCF-1, has been implicated in the 
regulation of various stages of T cell development (38, 60–62). 
Since the absence of HEB results in changes in Gata3 levels dur-
ing T cell development (37, 38) and Tce1 contains several E-boxes 
(putative HEB-binding sites), we asked whether HEB binds to 
any of those sites. ChIP assays conducted using an anti-HEB 
serum confirmed HEB binding to the Tcrb locus, a known HEB 
target gene (Figure 8C and ref. 63). We determined that HEB 
also binds to region e within the 1.2-kb enhancer core element 
in DN, DP, and CD4 stage cells (Figure 8C). Gata3 expression 
increases in HEB-deficient DN3 cells generated from fetal liver 
hematopoietic progenitors grown on OP9-DL1 feeder layers, and 
a model proposing how HEB negatively regulates Gata3 has been 
advanced (37). In contrast, the induction of Gata3 during the 
DP-to-SP transition is perturbed in the absence of HEB and E2A 
(38). While HEB forms a homodimer or heterodimer with other 
E-box proteins (such as E2A) to transactivate target genes (59), 
it can also heterodimerize with inhibitor of DNA binding (Id) 
proteins, which prevent E-box factors from binding to DNA (64, 
65). Since Id3 is expressed in thymocytes and plays an important 
Figure 6. No fragment of Tce1 is alone sufficient for Th2-specific transcription. (A) Illustration of truncated 2.9-kb and 4.2-kb Tce1 fragments. Restriction 
enzyme recognition sites are shown. (B) EGFP expression in naive CD4+ T cells and Th2 cells that were generated under Th2-polarizing conditions using in 
vitro T cell differentiation. Note that Tg2.9 and Tg4.2 mice are F0 Tg mice. Data are representative of 2 independent experiments.
Table 3. EGFP expression in naive CD4+ T cells and Th2 cells of F0 
Tg mice
Tg No. EGFP+ Tg mice/no. Tg mice (PCR+)
Naive CD4+ Th2
Tg2.9 8/8A 1/8A
Tg4.2 0/6 0/6
Tg1.2 4/7 1/7
Tg1.7 0/4 0/4
TgΔ1.2 0/7 0/7
TgΔ2.7 5/7 3/7
TgΔ1.5 9/9B 9/9B
TgΔ1.7 9/9C 6/9C
AEight of nine Tg2.9 mice, Bnine of twenty TgΔ1.5 mice, and Cnine of ten 
TgΔ1.7 mice whose EGFP expression in peripheral T cells was positive were 
analyzed.
Downloaded from http://www.jci.org on April 21, 2016.   http://dx.doi.org/10.1172/JCI83894
The Journal of Clinical Investigation   R e s e a R c h  a R t i c l e
8 7 3jci.org   Volume 126   Number 3   March 2016
expression through Tce1 during early 
T cell development but perhaps not dur-
ing later stages.
Taken together, these data show that 
at least 3 critical T cell–affiliated tran-
scription factors, TCF-1, HEB, and CSL/
RBP-J, occupy binding sites within Tce1 
at different developmental stages. Since 
all 3 have been shown to vitally affect 
T cell development, it seems likely that 
these factors and their associated signal-
ing pathways directly modulate Gata3 
expression through their binding to mul-
tiple consensus sites within Tce1.
Discussion
Here, we report that a complex enhancer, 
encoded by the distant Tce1 activator of 
transcription factor Gata3, is necessary 
for T cell development and is critical for 
the generation of ETP and for CD4 devel-
opment, as demonstrated by CRISPR/
Cas-mediated genome editing. This 
analysis also illuminated the mechanism 
of action of Tce1 during T cell develop-
ment and identified several transcription 
factors that are responsible for engaging 
this enhancer activity in T cells.
Many studies have shown that GATA3 
is required at multiple stages for normal T cell development (1, 2). 
Its abundance varies significantly between stages and is tightly 
controlled (5–11, 74). Although several transcription factors have 
been proposed as upstream regulators of Gata3 by demonstration 
that they bind near the Gata3 1a and/or 1b promoters (39, 40, 50, 
75, 76), a functional requirement for any of those binding sites has 
not been confirmed by in vivo mutagenesis. Furthermore, the data 
shown here and previously clearly demonstrate that the promoters 
alone are insufficient to activate Gata3 expression in T cells (36), 
while Tce1 mediates this activity.
Tce1 contains a 1.2-kb enhancer core element, which is suffi-
cient to drive transcription of a reporter gene from the ETP stage 
through to naive T cells. While this core element is also required 
for Th2 transcription, it is insufficient alone for directing Gata3 
transcription in those cells. Additional studies demonstrated that 
(40, 50, 71, 72). Although ICN and CSL/RBP-J have been shown 
to bind to the Gata3 1a promoter in Th2 cells (40, 50), that binding 
is clearly insufficient for T cell–specific Gata3 expression (36), and 
it is unknown whether the same factors bind to Tce1. We therefore 
examined the association of CSL/RBP-J with predicted binding 
sites within Tce1. CSL/RBP-J binding to the Cd25 locus, a robust 
direct Notch target gene (51), was used as a positive control with 
an anti–RBP-J antibody in ChIP assays (Figure 8D). We found 
that CSL/RBP-J bound to sequences within fragments d, e, and g 
(Figure 8A and Supplemental Table 3) of Tce1 in DN cells but not 
in DP cells (Figure 8D). This result is consistent with the observa-
tions that Notch signaling is required for early T cell development 
and for induction of Gata3 in ETP (67, 68, 73) but the absence of 
Notch signaling does not perturb late T cell development (68). 
Thus, these results suggest that Notch signaling regulates Gata3 
Figure 7. The 1.2-kb Tce1 fragment is nec-
essary for Th2 reporter gene transcription. 
(A) Illustration of 1.2-kb, 2.7-kb, 1.5-kb, 
and 1.7-kb deletion mutant Tce1 fragments. 
Restriction enzyme recognition sites are 
shown. (B) EGFP expression in naive CD4+ T 
cells and Th2 cells from F0 Tg
Δ1.2, TgΔ2.7, TgΔ1.5, 
and TgΔ1.7 mice as well as Tg1b.EGFP, TgTce1, and 
wild-type mice. Data are representative of 2 
independent experiments.
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stage-specific manner. The demonstration that in vivo deletion 
of Tce1 results in reduced ETP numbers implies that those factors 
are involved in Gata3 regulation through this enhancer. Notch sig-
naling has been proposed to activate Gata3 in ETP, although the 
cis element that is responsible for this activation by Notch has not 
been previously identified. These data indicate that Notch signal-
ing can activate Gata3 through Tce1 in ETP stage cells.
HEB and TCF-1 are important for CD4 lineage differentia-
tion (38, 49). E proteins HEB and E2A function as gatekeepers to 
adjoining 2.7-kb or 1.5-kb fragments within Tce1 must collaborate 
with the core 1.2-kb fragment to confer Th2-specific enhancement.
During T cell development, multiple distinct combinations of 
transcription factors are required to regulate specific target genes 
and guide progenitor cells toward a T lineage fate. Transcription 
factors TCF-1, HEB, and RBP-J are each known to be important 
for early stages of T cell development (reviewed in ref. 77), and 
the data herein indicate that each of these regulatory proteins 
binds to one or more sites within Tce1, each in a developmental 
Figure 8. Transcription factors TCF-1, HEB, and RBP-J bind to multiple sites within Tce1. (A) The segments of highest homology between corresponding 
human and mouse DNA sequences within Tce1 were examined in ChIP assays, and putative transcription factor–binding to these sites were examined. 
Restriction enzyme sites are shown. The results of ChIP assays comparing immunoprecipitation with either control IgG or (B) anti–TCF-1–, (C) anti-HEB–, 
or (D) anti–RPB-J–specific antibodies. The graph on the left of each row is the ChIP result from a published positive control locus (PC) and negative 
control locus (NC) for each antibody (39, 51, 63). The type of cells used for each assay is shown at the top of each graph. The location of each cluster of 
binding sites that was analyzed by ChIP assay is shown in A. The error bars represent the mean ± SD from triplicate qPCR samples. Data are representa-
tive of 2 independent experiments.
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Alternatively, the interaction among multiple cis elements, 
each containing overlapping but slightly different activity, may 
be required to produce authentic patterns of gene expression, as 
previously reported (e.g., refs. 86, 87). For example, Hoxd genes 
are important for developing hand and foot digits, and cis ele-
ments for regulation of the Hoxd genes are distributed over an 
800-kb “gene desert.” Each element appears to associate with 
the genes as well as other cis-regulatory elements and function 
to drive Hoxd gene transcription either quantitatively or qualita-
tively. Serial deletion of the Hoxd cis elements reveals incomplete 
redundancy within the cluster (87). The gene desert surrounding 
the Gata3 locus contains multiple cis elements, not just Tce1, as 
well as multiple enhancers that regulate the gene in numerous 
other tissues (refs. 46, 88–91 and our unpublished observations). 
Intriguingly, Pazin and colleagues demonstrated that a region 736 
kb 3′ to the Gata3 structural gene possesses enhancer-like activity 
in a T cell–derived cell line using an episomal vector (92). Fur-
thermore, recent genome-wide association studies have revealed 
that multiple, distinct disease-associated SNPs are located either 
within or near the GATA3 structural gene and are associated with 
leukemia (93–95), Hodgkin’s lymphoma (96), rhinitis (97), and 
asthma (98); furthermore, another asthma-associated SNP is 
located in a gene desert lying 1 Mb 3′ to GATA3 (99). The underly-
ing hypothesis in all of these studies is that those SNPs may reside 
in yet-to-be-defined cis-regulatory elements and may affect 
GATA3 expression in those T cell–related and/or aberrant GATA3 
expression-related diseases. Therefore, Tce1 and other currently 
undefined cis elements may contain partially overlapping activ-
ity and interact with one another to coordinately regulate Gata3 
transcription during T cell development.
Tce1, which consists of the enhancer core and accessory cis 
elements, is necessary for ETP and CD4 T cell development and 
Gata3 expression. We showed that TCF-1, HEB, and RBP-J (as well 
as other factors that were not examined in this study) occupy this 
enhancer and regulate Gata3 during T cell development. Under-
standing Tce1 function provides an essential pathway to elucidating 
the direct temporal regulation of Gata3, a critical, central regulatory 
protein that is required for T cell development. The present study 
should help to better define and further integrate transcriptional 
networks that regulate Gata3 during T cell development. Further 
studies addressing Gata3 regulation and function would provide 
important advances in our understanding of T cell development 
and should lead to clarification of the mechanisms underlying the 
molecular basis for the multiple diseases of hematopoietic origin in 
which GATA3 is implicated, such as leukemia and asthma.
Methods
Mice. The locus surrounding Tce1 was edited using CRISPR/Cas9, 
as described previously (42). gRNA sequences corresponding to 
sequences surrounding the 7.1 kbp that define the boundaries of Tce1 
(Supplemental Figure 1A) were cloned into the BbsI site of the bicis-
tronic expression vector px330 (Addgene; the gift of Feng Zhang, Broad 
Institute of MIT and Harvard, Cambridge, Massachusetts, USA; ref. 
100), which expresses Cas9 and single gRNA. The two CRISPR/Cas9-
gRNA plasmids were coinjected with single-stranded oligos containing 
loxP sequences, an EcoRI site, and 60-bp homology arms (Supplemen-
tal Figure 1B) into the pronuclei of fertilized eggs. The injected zygotes 
maintain cells at the DP stage until a functional αβTCR is gener-
ated (62). E proteins are also required for CD4 lineage choice and 
for preventing MHC class II–restricted thymocytes from entering 
the CD8 lineage. During this transition from the DP stage to the 
SP stage, the absence of E-box proteins or E-box inhibitors Id2 
and Id3 results in upregulated or downregulated Gata3 expres-
sion, respectively (38). The finding that genetic ablation of Tce1, 
which harbors in vivo binding sites for HEB, impaired CD4 T cell 
development suggests that HEB, possibly acting as an HEB-E2A 
heterodimeric activator, positively regulates Gata3 expression 
through Tce1 during the DP-to-SP transition.
In the absence of TCF-1 and LEF-1, CD4 development is 
impaired and MHC class II–restricted thymocytes are redirected 
to the CD8 lineage, although their absence does not significantly 
change the levels of Gata3 in DP and CD4+CD8lo cells (49). TCF-1 
and LEF-1 may contribute to the regulation of Gata3 through Tce1 
in order to maintain abundant Gata3 expression at the CD4 stage. 
Alternatively, once bound to Tce1, TCF-1 and LEF-1 may play an 
architectural role to facilitate the recruitment of other factors, 
since TCF-1 and LEF-1 contain an HMG domain that has been 
shown to bend DNA (78).
Interestingly, the finding that phenotypes in Tce1 knock-
out mice were relatively more subtle than in hematopoietic 
lineage–specific Gata3 conditional knockout mice (12) implies 
that there may be a partially redundant enhancer activity some-
where within the extended Gata3 locus (and lying outside of the 
1.5 Mb already surveyed; ref. 36). Although Tce1 is sufficient for 
transcription of a reporter gene throughout T cell development, 
we previously concluded that additional cis elements might be 
required for some stages (for example, for transition from the 
ETP stage to the DN3 stage or to promote Th2 differentiation) 
because of differences in the expression pattern of reporter genes 
and endogenous Gata3 mRNA (36). The result of Tce1 deletion 
by CRISPR/Cas-mediated genome editing in this study supports 
the redundant Gata3 T cell enhancer hypothesis.
Enhancer redundancy has been well documented elsewhere. 
Some such elements exhibit no significant phenotypic effects after 
loss of the enhancer (e.g., refs. 79, 80). Other studies conclude that 
enhancers can specify both redundant and essential roles (e.g., ref. 
81), as appears to be the case with Tce1, whose loss confers clear 
deficits in T cell homeostasis, while not completely abrogating T 
cell function. One mechanism that has been proposed for enhancer 
redundancy is the presence of “shadow enhancers” (refs. 82, 
83, and reviewed in ref. 84). According to this hypothesis, two or 
more enhancers for any given gene may direct similar expression 
patterns, and those enhancers may appear to be redundant under 
normal laboratory conditions. However, under stressful conditions 
(e.g., elevated temperature, food scarcity), environmental influ-
ences leading to disrupted function of a single enhancer may per-
turb normal gene expression. Thus, those shadow enhancers are 
thought to provide robustness to environmental or genetic pertur-
bation and stress, and the thymus is known to be particularly sen-
sitive to such stresses (85). Therefore, reliable, robust transcription 
of Gata3 during the ETP and CD4 stages of T cell development 
may require both Tce1 and a putative shadow enhancer in order to 
generate appropriate thymic cellular output under conditions that 
are not usually encountered in the laboratory.
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viously described (36). Briefly, isolated CD4 cells were stimulated 
with plate-bound anti-CD3ε antibody (10 μg/ml; 145-2C11; BD Bio-
sciences) and anti-CD28 antibody (10 g/ml; 37.51; BD Biosciences). 
To induce Th2-polarizing conditions, 10 μg/ml anti–IFN-γ antibody 
(XMG1.2; BD Biosciences), 10 μg/ml anti–IL-12 antibody (C17.8; BD 
Biosciences), 10 ng/ml recombinant human IL-2 (200-02, Pepro-
Tech), and 10 ng/ml recombinant mouse IL-4 (554432, BD Pharmin-
gen) were added. On day 4 of culture, stimulation was stopped and the 
cells were diluted. On day 6, cells were restimulated with plate-bound 
anti-CD3ε and anti-CD28 antibodies (3 μg/ml each) for 6 hours. Cells 
were harvested, and we analyzed EGFP expression by flow cytome-
try as previously described (36). A small fraction of harvested cells 
was used for RNA extraction to confirm in vitro T cell differentiation 
by measuring the expression of cytokine mRNAs (Il4 and Ifng) and 
endogenous Gata3 mRNA by qRT-PCR (data not shown).
ChIP. Details are provided in the Supplemental Methods.
Prediction of putative transcription factor–binding sites. A search for 
putative transcription factor–binding sites in Tce1 was performed using 
rVISTA 2.0 (http://rvista.dcode.org) (101) or rVISTA (http://genome.
lbl.gov/vista/rvista/submit.shtml) (102).
Statistics. Data were analyzed by 2-tailed Student’s t test. A P value 
of less than 0.05 was considered significant.
Study approval. All animal experiments were approved by and 
conducted in accordance with the guidelines of the Committee on the 
Use and Care of Animals of the University of Michigan or the Animal 
Experiment Committee of Tsukuba University.
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were transferred into the oviduct of pseudopregnant ICR females at 
1.0 to 1.5 dpc. Mice were genotyped by PCR using primers shown in 
Supplemental Figure 1A. The deletion of Tce1 was confirmed by DNA 
sequencing of the PCR product (Supplemental Figure 2).
TgTce1 and Tg1b.EGFP mice were established as previously described 
(36), and Tg lines were used in this study. Founder Tg mice contain-
ing various truncated Tce1 fragments were generated using standard 
techniques in the University of Michigan Transgenic Animal Model 
Core. Plasmid DNAs were microinjected into (C57BL/6J × SJL) F2 fer-
tilized eggs. Those founder Tg mice were used for analysis instead of 
establishing Tg lines.
Plasmid construction. Details are provided in the Supplemental 
Methods.
Flow cytometry. To analyze expression of the EGFP reporter gene 
in the various Tg founder mice, single-cell suspensions of thymocytes, 
bone marrow cells, splenocytes, lymph node cells, or peripheral blood 
were incubated with Fc Block (BD Bioscience). Before incubation, 
splenocytes and peripheral blood were hemolyzed with ammonium 
chloride. Cells were stained with a variety of antibodies as previously 
described (36), washed, and analyzed on a FACSCanto II, Fortessa, 
or FACSAria III (BD Biosciences). Dead cells were excluded by DAPI 
or propidium iodide. Immature T cells were analyzed as previously 
described (12). The following antibodies were purchased from Bio-
Legend, eBioscience, and/or BD: B220 (RA3-6B2; BioLegend and 
eBioscience), CD3 (17A2; BioLegend and eBioscience), CD8a (53-
6.7; Bio Legend and eBioscience), CD11b (M1/70; Bio Legend and 
eBioscience), CD11c, (N418; BioLegend and eBioscience), CD19 
(1D3; Bio Legend and eBioscience), CD25 (PC61.5; BioLegend and 
eBioscience), cKit (2B8; BioLegend and eBioscience), Gr1 (RB6-8C5; 
Bio Legend and eBioscience), NK1.1 (PK136; eBioscience), TCRβ 
(H57-597; BioLegend and eBioscience), TCRγ/δ (GL3; BioLegend, 
eBioscience, and BD), TER119 (TER-119; BioLegend and eBiosci-
ence), and Thy1.2 (53-2.1; BioLegend).
For every experiment in which EGFP expression was analyzed, a 
LinearFlow Green Flow Cytometry Intensity Calibration Kit (Molec-
ular Probes) was used. These calibration beads were excited by 
488-nm laser, and fluorescence measurements were performed in the 
same manner as those for EGFP in order to confirm that the intensity 
of EGFP PMT voltage was at comparable levels in all experiments. 
Acquired data were analyzed using FlowJo software (Tree Star Inc.).
To sort each stage of thymocytes for ChIP assay, cells were incu-
bated with Fc Block and stained with PE-Cy7-anti-CD4 (clone RM4-5; 
BioLegend), APC-anti-CD8a (clone 53-6.7; BioLegend), and PerCP-
Cy5.5-anti-TCRβ (clone H57-597; BioLegend). DAPI was used as a dead 
cell marker. DN (CD4–CD8–) cells, DP (CD4+CD8+) cells, and CD4 SP 
(CD4+CD8–TCRβ+) cells were sorted in a FACSAria III (BD Bioscience).
Quantitative RT-PCR. Quantitative RT-PCR (qRT-PCR) was per-
formed as described previously (74).
In vitro CD4 T cell differentiation. CD4+CD25– lymph node cells 
were purified using the Dynal Mouse CD4-Negative Isolation Kit 
(Invitrogen) in combination with affinity-purified anti-mouse CD25 
antibody (PC61.5; eBioscience or BioLegend) and cultured as pre-
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